Associate Professor Behzad Hajarizadeh is the recipient of the 2022 Brett Tindall Memorial Lecture. His lecture will focus on his extensive and world-leading research into hepatitis C treatment uptake.
Hepatitis C treatment uptake in Australia: Making a case for equitable access
The World Health Organization has set the target of eliminating hepatitis C as a public health threat by 2030, and highly curative direct-acting antivirals (DAA) are a key tool to eliminate the disease. But in some settings, these curative treatments are not widely accessed, due to a number of challenges. Internationally, a key barrier is restricted access for marginalised populations such as people who inject drugs or people who are incarcerated. In his presentation, A/Prof Hajarizadeh will present the evidence that highlights and addresses some of these challenges, including the evaluation of national and global strategies to enhance DAA treatment access and uptake.
*Please note this is a hybrid seminar with registration options for in-person and online attendance. Lunch will be provided from 12pm for in-person attendees, with the seminar to follow at 1pm.
Please see event page for updates: https://kirby.unsw.edu.au/event/brett-tindall-memorial-lecture-2022-associate-professor-behzad-hajarizadeh
The Brett Tindall Memorial Lecture is an annual lecture awarded to an outstanding mid-career Kirby Institute researcher, based on a recently impactful body of work.
It is awarded in memory of Dr Brett Tindall, who was one of the Kirby Institute’s first researchers in the 1980s. Brett's research focused on the process of seroconversion and the body's responses to the entry of HIV. He died of AIDS in 1994.
